Copenhagen, 2012-02-27 10:19 CET (GLOBE NEWSWIRE) --
Investor News
No. 3/2012
Copenhagen, 27 February 2012 - Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, invites its shareholders to suggest items to the agenda for the
Annual General Meeting 2012
Date: 25 April 2012 at 3 p.m. local time (9am EST)
Location: Zealand Pharma, Smedeland 36, 2600 Glostrup, Copenhagen
Shareholders who wish to have an item included on the agenda for the Annual General Meeting must notify the company in writing no later than 13 March 2012.
Please send suggestions to:
Zealand Pharma A/S, Smedeland 36, DK-2600 Copenhagen,
att: CFO Mats Blom (E-mail: mabl@zp.dk)
Further information can be found on Zealand Pharma’s website: www.zealandpharma.com.
# # #
For further information, please contact:
Hanne Leth Hillman, Vice President for IR & Corporate Communication,
Tel: +45 5060 3689, hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature clinical pipeline of innovative peptide based drugs. The company's lead product is lixisenatide (Lyxumia® 1)), a once-daily GLP-1 agonist for the treatment of Type 2 diabetes, invented by Zealand Pharma and licensed to Sanofi. In November, Sanofi submitted a marketing authorization application (MAA) for lixisenatide (Lyxumia®) in Europe and submission for regulatory approval of lixisenatide in the United States is expected in Q4 2012. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a license agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com.
Note 1) Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is not currently approved or licensed anywhere in the world.
